Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX ® Cosmetic, the JUVÉDERM ® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program IRVINE, Calif. , April 23, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX ® Cosmetic , the... Read More

Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ ® ; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen 1 The safety profile in GCA was generally consistent with that in approved... Read More

Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN)... Read More

From the makers of BOTOX ® Cosmetic, two new SkinMedica ® acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica ® by the makers of BOTOX ® Cosmetic. The SkinMedica ® Acne Clarifying Treatment and SkinMedica ® Pore Purifying Gel... Read More

NORTH CHICAGO, Ill. , April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that... Read More

Offering $200 Off the First CoolSculpting® Treatment IRVINE, Calif. , April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebration featuring CoolSculpting® Elite. From April 1 through April 30, 2024 , consumers can access CoolSavings promotions to help accelerate their body contouring journey. Leveraging last year's success, which saw more than 62,000... Read More

Allergan Aesthetics is raising the conversation on patient safety and ethical standards As part of its established Aesthetics-Ethics program, this year's Anti-Age Medicine World Congress (AMWC) launches Moving the Needle on Ethics Book Thought-provoking articles and interviews with leading medical practitioners from around the world discuss the impact of ethical practices and aim to raise awareness and create discussion... Read More

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a... Read More

The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) Data show that ELAHERE treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35% ELAHERE represents AbbVie's first approved solid tumor treatment following the... Read More

Two expert-led Allergan Medical Institute (AMI) symposia will explore a personalized approach to aesthetics, featuring live injection sessions with Dr Mauricio De Maio , Dr Mansi Mukherjee and Dr Steven Liew World class experts to convene on socially transformative aesthetic medicine at Science of Aging TM event Seventeen posters exhibiting new clinical data on toxins and fillers showcase the diverse Allergan Aesthetics... Read More

NORTH CHICAGO, Ill. , March 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., senior vice president,... Read More

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatologic conditions and aesthetic indications NORTH CHICAGO, Ill. , March 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three... Read More

THE FIRST AND ONLY HYALURONIC ACID DERMAL FILLER APPROVED FOR THE IMPROVEMENT OF MODERATE TO SEVERE TEMPLE HOLLOWING 1 IRVINE, Calif. , March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM ® VOLUMA ® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21. 1 JUVÉDERM ® VOLUMA ® XC is the... Read More

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET ® to enter into clinical trials. WALTHAM, Mass. , March 5, 2024 /CNW/ -- Dragonfly Therapeutics, Inc. , a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a... Read More

Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France , Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA... Read More

NORTH CHICAGO, Ill. , Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., senior vice president, chief... Read More

NEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics , a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A. The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving... Read More

A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma (FL), demonstrating strong and durable treatment responses In November 2023 , the FDA granted this investigational indication a Breakthrough Therapy Designation (BTD) NORTH CHICAGO, Ill. , Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV)... Read More

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO , Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix... Read More

FOR THE SECOND YEAR, BOTOX ® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY IRVINE, Calif. , Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX ® Cosmetic grant program supporting women entrepreneurs. BOTOX ® Cosmetic partnered with IFundWomen to launch the... Read More

Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman Transition will occur on July 1, 2024 NORTH CHICAGO, Ill. , Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael , AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez, who has... Read More

A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of products that aim to improve the lives of patients living with inflammatory bowel diseases (IBD) Oral data presentations include a new post-hoc analysis of clinical and endoscopic outcomes from the SEQUENCE trial comparing risankizumab (SKYRIZI ® ) versus ustekinumab, results from the... Read More

NORTH CHICAGO, Ill. , Feb. 15, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable May 15, 2024 , to stockholders of record at the close of business on April 15, 2024 . Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent. AbbVie is a member of the S&P Dividend Aristocrats... Read More

Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide... Read More

VYALEV is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease (aPD) in Canada . Advanced Parkinson's disease patients now have a non-surgical treatment option that addresses an unmet need within this community. In clinical trials, patients taking VYALEV achieved the primary endpoint of a reduction in motor fluctuations and morning akinesia, as well as... Read More

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA,... Read More

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11 , a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $54.318 Billion , a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational Basis Full-Year Global Net... Read More

New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics Report underpins ongoing commitment to aesthetics accessibility and inclusivity to achieve desired patient outcomes IRVINE, Calif. , Jan. 31, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments,... Read More

Expert-led symposium will explore key emerging themes in aesthetics, supported by injection session live from Allergan Aesthetics Center of Excellence in Italy New clinical data will be presented to support evolving Allergan Aesthetics portfolio 2024 marks 10 years of Allergan Medical Institute (AMI) and a decade of commitment to science and advanced education IRVINE, Calif. , Jan. 25, 2024 /PRNewswire/ -- Allergan... Read More

ALLĒ SOLIDIFIES ITS POSITIONING WITH SATISFACTION SCORES IN THE NINETY-SECOND PERCENTILE BASED ON CONSUMER SURVEY IRVINE, Calif. , Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve... Read More

PRODUODOPA ® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease PRODUODOPA demonstrated sustained improvements in "Off" time (when symptoms return between medication doses), "On" time (when symptoms are controlled) without dyskinesia (involuntary movement), and morning akinesia ("Off" time upon waking) NORTH CHICAGO, Ill.... Read More

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo 1,2 Higher response rates were also observed in patients receiving lutikizumab 300 mg weekly or 300 mg every other week than those treated with placebo in the... Read More

Collaboration to leverage Umoja's VivoVec TM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH CHICAGO, Ill. and SEATTLE , Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop... Read More

NORTH CHICAGO, Ill. , Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later... Read More

NORTH CHICAGO, Ill. , Jan. 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D. senior vice president,... Read More

Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65 th American Society of Hematology (ASH) congress Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma NORTH CHICAGO, Ill. , Dec. 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced... Read More

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions Transaction valued at $45.00... Read More

Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation antibodies BigHat to receive $30 million upfront payment with potential for further milestone payments and royalties NORTH CHICAGO, Ill. and SAN MATEO, Calif. , Dec. 5, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and BigHat... Read More

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE ® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio,... Read More

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression Data from the study will be presented at a future medical meeting and we will discuss with global health authorities the potential to... Read More

Updates are supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial NORTH CHICAGO, Ill. , Nov. 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory (R/R) follicular lymphoma (FL). The FDA... Read More

ALLĒ MEMBERS CAN CELEBRATE THE HOLIDAY ALL OF NOVEMBER IRVINE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), celebrated the fifth annual BOTOX ® Cosmetic Day like never before, achieving record-breaking numbers. November-to-date saw the highest number of BOTOX ® Cosmetic treatments in history. 1-2 The highest number of gift cards were sold in BOTOX ® Cosmetic Day history. 1-2... Read More

More patients treated with UBRELVY ® 100 mg during the prodrome avoided the development of moderate or severe headache within 24 hours post-dose vs. placebo in those who could identify prodrome symptoms that were reliably followed by headache 1 UBRELVY is the first and only acute treatment for migraine that has demonstrated data in the prodrome phase in a Phase 3, double-blind, placebo-controlled trial AbbVie is the only... Read More

Refreshed Look Spotlights Most Diverse Breast Implant Portfolio for a Customized Look IRVINE, Calif. , Nov. 8, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), embraces the immensely personal choice that patients experience when choosing breast surgery. The new Natrelle ® campaign, "For Every BODY,"... Read More

CELEBRATING THE FIFTH ANNUAL BOTOX ® COSMETIC DAY, NEW AND LOYAL ALLĒ MEMBERS BENEFIT FROM MORE EXCITING OFFERS IRVINE, Calif. , Nov. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating the fifth annual BOTOX ® Cosmetic Day on Wednesday, November 15 . To commemorate this milestone, the brand is expanding its offerings like never before. New and loyal members of Allē, the Allergan... Read More

Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95 , a Decrease of 19.4 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share elated to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $13.927 Billion , a Decrease of 6.0 Percent on a Reported Basis and 5.8 Percent on an Operational Basis Third-Quarter Global Net... Read More

All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508). Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect within 2-3 weeks. If approved, BoNT/E will be the first neurotoxin of its kind available to patients. IRVINE, Calif. , Oct. 24,... Read More

Ongoing Support for Breast Cancer Patients Through Initiatives Focused on Education and Elevating Patient Voices IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Yesterday, on Breast Reconstruction Awareness Day (National BRA Day), Allergan Aesthetics, an AbbVie company (NYSE: ABBV), launched Reblossom , a coffee table book featuring a collection of patient stories and photographs that celebrates the resilience of breast... Read More

Approval is based on results from three Phase 3 clinical trials demonstrating RINVOQ achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment 1,2,3,4,5 Safety results were generally consistent with the known safety profile of RINVOQ, with no new safety risks observed 1-5,6,7,8,9 RINVOQ is the first JAK inhibitor indicated in both Crohn's disease and ulcerative... Read More

MONTREAL , Oct. 17, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that EPKINLY ™ (epcoritamab injection/epcoritamab for injection) has received Health Canada authorization with conditions. It is the first and only subcutaneous (SC) T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL transformed from... Read More

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs 1 Risankizumab met both primary endpoints of non-inferiority for clinical remission a (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remission b at week 48 versus ustekinumab 1 Risankizumab... Read More

At week 24, upadacitinib met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV) 1 At week 52, the percent reduction from baseline in F-VASI was numerically greater than results at week 24 for all upadacitinib doses 1,2 The safety profile was consistent with the known safety profile for... Read More

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ ® (upadacitinib) in treating moderate to severe atopic dermatitis based on results across 140 weeks 1 Response rates for EASI 75 and vIGA-AD 0/1 (co-primary endpoints) and for EASI 90 and WP-NRS 0/1 at week 16 were sustained through week 140 among patients treated with RINVOQ 1 Safety results... Read More

Late-breaking data from a head-to-head study evaluating SKYRIZI ® (risankizumab) versus STELARA ® (ustekinumab) in moderate to severe Crohn's disease will be presented Analyses on clinical and endoscopic outcomes from AbbVie's maintenance trials for SKYRIZI ® (risankizumab) and RINVOQ ® (upadacitinib) in moderate to severe Crohn's disease and for RINVOQ in moderate to severe ulcerative colitis Primary efficacy and safety... Read More

Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease Activation of PINK1 remediates mitochondrial damage and restores mitochondrial function NORTH CHICAGO, Ill. , Oct. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of... Read More

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard , and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings,... Read More

NORTH CHICAGO, Ill. , Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through AbbVie's Investor Relations website investors.abbvie.com . An archived edition of the session will be available later that day. About... Read More

Girls Inc. alumnae in New York , San Antonio and Central Alabama will participate in a virtual panel titled 'Equipping the New Generation of STEM Leaders' with leading women physicians sharing their career journeys including growth moments and challenges A social media campaign shares authentic stories and aspirations of girls entering the workforce IRVINE, Calif. , Oct. 3, 2023 /PRNewswire/ -- Today Allergan Aesthetics, an... Read More

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma NORTH... Read More

TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy Conditional marketing authorization approval from the European Commission is supported by data from the pivotal Phase 1/2 EPCORE™ NHL-1 clinical trial TEPKINLY represents AbbVie's second approved... Read More

All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). Results support onabotulinumtoxinA as a potential treatment option for moderate to severe platysma prominence. Data will be included as part of an upcoming U.S. Food and Drug Administration regulatory submission expected near the end of the year. If approved,... Read More

Online and mobile voting is open to the public now through September 27 to help determine this year's two Thriving Students 40 students living with cystic fibrosis (CF) received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement Two deserving students will be awarded scholarships totaling $25,000 each NORTH CHICAGO, Ill. , Sept. 13, 2023 /PRNewswire/ -- AbbVie... Read More

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs 1 Risankizumab met both primary endpoints of non-inferiority for clinical remission (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic... Read More

NORTH CHICAGO, Ill. , Sept. 8, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable November 15, 2023 , to stockholders of record at the close of business on October 13, 2023 . Since the company's inception in 2013, AbbVie has increased its dividend by 270 percent. AbbVie is a member of the S&P Dividend Aristocrats... Read More

GET TO KNOW THE WOMEN-OWNED BUSINESSES RECEIVING GRANTS AND CONTRIBUTE TO THEIR SUCCESS, FURTHER CLOSING THE "CONFIDENCE GAP" IRVINE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the next chapter of the BOTOX ® Cosmetic and IFundWomen grant program with the launch of crowdfunding campaigns for the women entrepreneurs. The brand recently announced the recipients... Read More

NORTH CHICAGO, Ill. , Sept. 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 . Robert A. Michael , president and chief operating officer, Scott Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , senior vice president,... Read More

At day 30, approximately 90% of all study patients were satisfied with treatment resulting in a natural look and more than 80% of all study patients were satisfied with natural-looking outcomes throughout the 12-month study period for the temporary improvement in the appearance of their moderate to severe upper facial lines 1 At day 30, more than half of patients experienced a notable difference in self-perceived appearance... Read More

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an induction and maintenance treatment 1,2 Safety results were generally consistent with the known safety profile of risankizumab, with no new safety risks observed 1,2 Risankizumab is an IL-23 inhibitor being evaluated as a treatment... Read More

AQUIPTA ® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) approved for the prophylaxis of migraine in adults who have four or more migraine days per month Approval is based on two pivotal Phase 3 studies that demonstrated statistically significant reduction in mean monthly migraine days with AQUIPTA compared to placebo in adult... Read More

The Number One Chosen Dermal Filler Collection Celebrates with Exclusive Offers IRVINE, Calif. , Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM ® Day on Wednesday, August 16, 2023 . The celebration recognizes the aesthetics providers and patients who have... Read More

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91 , a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $13.865 Billion , a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational Basis Second-Quarter Global... Read More

NORTH CHICAGO, Ill. and LA JOLLA, Calif. , July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps... Read More

An open-label, efficacy assessor-blinded study comparing SKYRIZI ® (risankizumab) to Otezla ® (apremilast) for the treatment of adult patients with moderate plaque psoriasis who were candidates for systemic therapy was published in the British Journal of Dermatology 1 Significantly more patients in the study achieved co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16 with risankizumab versus apremilast 1 In apremilast... Read More

Approval is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2,3 In clinical trials, patients taking RINVOQ achieved the primary endpoint of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 52 1,2,3 Safety results in ulcerative colitis were generally consistent with the known safety profile of RINVOQ, with no new important safety risks observed 4,5,6,7,8,9 Approval... Read More

-First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ ® ) in adults and adolescents with moderate to severe HS 1 -HS is a difficult-to-treat chronic, inflammatory disease with few therapeutic options available 2,3 -AbbVie applies proven expertise in immunology and HS in continued efforts to bring new treatment options to patients living with... Read More

If approved, epcoritamab (TEPKINLY ® ) will become the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) DLBCL after two or more lines of systemic therapy The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 Phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients... Read More

NORTH CHICAGO, Ill. , July 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday, July 27, 2023 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through AbbVie's Investor Relations website investors.abbvie.com . An archived edition of the session will be available later that day. About... Read More

Based on the topline results of epcoritamab from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities to discuss next steps Additional data from the clinical trial will be presented at a future medical meeting Follicular lymphoma is a common form of non-Hodgkin's lymphoma and currently has limited treatment options, particularly in the relapsed/refractory setting NORTH CHICAGO, Ill. ,... Read More

AbbVie's 2023 Week of Possibilities brings more than 14,000 employees together to participate in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact Week of Possibilities is AbbVie's annual, global volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering NORTH... Read More

If approved by the European Commission (EC), atogepant will be the first and only once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) for the prophylaxis of migraine in adults who have four or more migraine days per month The positive CHMP opinion is based on results from two pivotal Phase 3 studies evaluating atogepant for the prophylaxis of migraine in adults with... Read More

NORTH CHICAGO, Ill. , June 22, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable August 15, 2023 , to stockholders of record at the close of business on July 14, 2023 . Since the company's inception in 2013, AbbVie has increased its dividend by 270 percent. AbbVie is a member of the S&P Dividend Aristocrats Index,... Read More

In ulcerative colitis patients with a clinical response to risankizumab induction treatment, a significantly higher proportion of patients treated with risankizumab (180 mg or 360 mg) achieved the primary endpoint of clinical remission a (per Adapted Mayo Score) at week 52 compared to withdrawal from risankizumab treatment 1 Key secondary endpoints were met, including endoscopic improvement b , histologic endoscopic mucosal... Read More

20 GRANT RECIPIENTS ARE SELECTED FROM MORE THAN 6,500 APPLICATIONS TO RECEIVE FUNDING, YEAR-LONG MENTORSHIP, AND COACHING IRVINE, Calif. , June 13, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the 20 incredible women entrepreneurs who will receive funding and mentorship through the... Read More

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in CLL Six-year median follow-up from the Phase 3 CLL14 study shows continued PFS after treatment with venetoclax plus obinutuzumab compared to treatment with chlorambucil plus obinutuzumab in previously untreated patients with CLL and co-existing conditions Final... Read More

MONTREAL , June 7, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that VRAYLAR is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits (NIHB) 1 program for the treatment of schizophrenia. Information regarding the specific reimbursement criteria may be found by consulting the following link: Non-Insured Health Benefits Program – Drug Benefit List This announcement comes 13 months after... Read More

NORTH CHICAGO, Ill. , June 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 . Robert A. Michael , vice chairman and president, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00... Read More

At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day in patients with moderately to severely active SLE receiving standard lupus therapies 1 Upadacitinib maintained greater... Read More

NORTH CHICAGO, Ill. , May 25, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, U-EXCEED and U-ENDURE – evaluating upadacitinib (RINVOQ ® ) in adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to conventional therapy or a... Read More

Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ ® (upadacitinib) and HUMIRA ® (adalimumab), both in combination with methotrexate (MTX), are reported for adult patients with moderate to severely active rheumatoid arthritis (RA) who had an inadequate response to MTX 1 Three-year results from SELECT-PsA 1 evaluating the efficacy and safety of RINVOQ are reported in psoriatic arthritis (PsA)... Read More

NORTH CHICAGO, Ill. , May 19, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY TM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma,... Read More

The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at week 12 and week 52 versus placebo 1 Clinical response was achieved by significantly more patients treated with RINVOQ (upadacitinib) versus placebo as early as week 2 in induction studies 1 This indication marks the seventh... Read More

THE FIRST AND ONLY HYALURONIC ACID INTRADERMAL MICRODROPLET INJECTION, APPROVED FOR IMPROVED SKIN SMOOTHNESS OF THE CHEEKS IRVINE, Calif. , May 15, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of SKINVIVE™ by JUVÉDERM ® to improve skin smoothness of the cheeks... Read More

Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in Canada 1, 2, 3 MONTREAL , May 9,... Read More

Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6 to 17 years Twenty-nine abstracts showcase AbbVie's vast portfolio and continued commitment to changing the way patients living with... Read More

NORTH CHICAGO, Ill. , May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023 . Robert A. Michael , vice chairman and president, Scott Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , senior vice president, development and regulatory... Read More

Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46 , a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.225 Billion , a Decrease of 9.7 Percent on a Reported Basis and 8.3 Percent on an Operational Basis First-Quarter Global Net... Read More

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional oral medications used for prevention The trial met its primary and secondary endpoints with results showcasing a significant reduction in mean monthly migraine days for those with episodic migraine taking atogepant 60 mg once... Read More

Women surgeons breaking the boundaries of leadership presented in partnership with the American Society of Plastic Surgeons (ASPS), The Aesthetic Society and the American Hernia Society (AHS) IRVINE, Calif. , April 18, 2023 /PRNewswire/ -- Allergan Aesthetics , an AbbVie company, supports women plastic surgeons and the development of current and future leaders in science, healthcare, and medicine with LIMITLESS, an ongoing... Read More

QULIPTA ® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact performance of daily activities Approval based on a clinical trial that demonstrated statistically significant reduction from baseline in mean... Read More

MONTREAL , April 17, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that VRAYLAR is now listed as an exception medication status on the list of medications of the Régie de l'assurance maladie du Québec (RAMQ) 1 for the treatment of schizophrenia. Information regarding the specific reimbursement criteria may be found by consulting the link below: Régie de l'assurance maladie du Québec – List of Medications This... Read More